| Literature DB >> 26716416 |
Wei Zhao1,2, Huijun Zhu3, Shu Zhang3, Hongmei Yong4, Wei Wang3, Yan Zhou5, Bing Wang5, Jinbo Wen6, Zhenning Qiu7, Guipeng Ding1, Zhenqing Feng1,7,8,9, Jin Zhu7,10.
Abstract
The cell surface protein Trop2 is overexpressed in a variety of human cancers. Trop2 expression increases tumor development and metastasis and reduces patient survival. However, little is known about the role of Trop2 expression and its prognostic value in gastric cancer (GC), particularly in Chinese populations. We analyzed Trop2 expression in GC tissues collected from Chinese GC patients. Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry on tissue microarrays were performed to assess levels of Trop2 mRNA and protein in GC, and correlations between Trop2 expression and clinical characteristics and prognosis were analyzed. Trop2 expression was higher in GC tissues than in neighboring non-tumor tissues. Increased Trop2 protein levels in GC were associated with increased differentiation, tumor node metastasis stage, tumor size, lymph node metastasis, distant metastasis, and H. pylori infection. GC patients with high Trop2 expression also had poor overall survival rates. These data suggest Trop2 is a useful prognostic biomarker for GC.Entities:
Keywords: Trop2; gastric cancer; prognosis
Mesh:
Substances:
Year: 2016 PMID: 26716416 PMCID: PMC4868745 DOI: 10.18632/oncotarget.6733
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Trop2 mRNA expression in 41 GC tissue pairs
Trop2 mRNA expression was examined by qRT-PCR and normalized to β-actin. Trop2 mRNA levels were higher in the 41 GC tissues (T) than in matched tumor neighbor tissues (N) (**p < 0.001).
Figure 2Representative images of Trop2 protein expression in gastric tissue TMA sections
(A) Middle differentiated gastric cancer with high Trop2 expression (IHC score, 300); (B) Poor differentiated gastric cancer with high Trop2 expression (IHC score, 270); (C) Signet ring cell gastric cancer with low Trop2 expression (IHC score, 60); (D) Matched tumor neighbor tissues with low Trop2 expression (IHC score, 30); (E) Chronic gastritis with low Trop2 expression (IHC score, 30); (F) Intestinal metaplasia with high Trop2 expression (IHC score, 260); (G) Low-grade intraepithelial neoplasia with low Trop2 expression (IHC score, 30); (H) High-grade intraepithelial neoplasia with low Trop2 expression (IHC score, 60); Row 1 and 3 are Trop2 staining with × 4 (bar = 500 μm), Row 2 and 4 are Trop2 staining with × 40 (bar = 50 μm).
Trop2 expression in gastric tissues
| Characteristic | Trop2 expression (%) | χ2 | |||
|---|---|---|---|---|---|
| Low or no | High | ||||
| Stomach | 76.705 | < 0.001* | |||
| Cancer | 600 | 202 (33.70) | 398 (66.30) | ||
| Matched tumor neighbor | 89 | 50 (56.2) | 39 (43.8) | 32.55 | |
| Chronic gastritis | 32 | 28 (87.50) | 4 (12.50) | 11.65 | |
| Intestinal metaplasia | 30 | 6 (20.00) | 24 (80.00) | 9.90 | 0.084 |
| Low-grade intraepithelial neoplasia | 31 | 22 (71.0) | 9 (29.0) | 17.912 | |
| High-grade intraepithelial neoplasia | 48 | 30 (62.50) | 18 (37.50) | 16.934 | |
χ2 and p values for stomach overall includes all types gastric tissues. The χ2 and p values for matched tumor neighbor, chronic gastritis, intestinal metaplasia, low-grade intraepithelial neoplasia, and high-grade intraepithelial neoplasia are in comparison to the cancer group.
Associations between high Trop2 expression and clinicopathologic characteristics in GC patients
| Characteristic | Trop2 expression (%) | Pearson χ2 | |||
|---|---|---|---|---|---|
| Low or no | High | ||||
| Total | 600 | 202 (34.70) | 398 (66.30) | ||
| 0.557 | 0.504 | ||||
| Male | 428 | 148 (34.60) | 280 (65.40) | ||
| Female | 172 | 54 (31.40) | 118 (68.60) | ||
| 2.158 | 0.084 | ||||
| < 60 | 334 | 104 (31.10) | 230 (68.90) | ||
| ≥ 60 | 226 | 98 (36.80) | 168 (63.20) | ||
| 9.187 | 0.057 | ||||
| Tubular | 524 | 176 (33.60) | 348 (66.40) | ||
| Mixed (tubular and mucinous) | 7 | 2 (28.60) | 5 (71.40) | ||
| Mucinous | 34 | 10 (29.40) | 24 (70.60) | ||
| Signet ring cell | 23 | 13 (56.50) | 10 (43.50) | ||
| Others | 12 | 1 (8.30) | 11 (91.70) | ||
| 9.192 | |||||
| Well | 57 | 28 (49.10) | 29 (50.90) | ||
| Moderate | 145 | 52 (35.90) | 93 (64.10) | ||
| Poor | 329 | 97 (29.50) | 232 (70.50) | ||
| Others | 69 | 25 (36.20) | 44 (63.80) | ||
| 38.939 | |||||
| 0 | 18 | 10 (50.60) | 8 (44.40) | ||
| Ia + Ib | 111 | 60 (54.10) | 51 (45.90) | ||
| Ia + IIb | 208 | 72 (34.60) | 136 (65.40) | ||
| IIIa+ IIIb | 210 | 50 (23.80) | 160 (76.20) | ||
| IIIc + IV | 53 | 10 (18.90) | 43 (81.10) | ||
| 35.576 | |||||
| T0 | 18 | 10 (55.60) | 8 (44.40) | ||
| T1a+T1b+T2 | 180 | 89 (49.40) | 91 (50.60) | ||
| T3+T4a+T4b | 402 | 103 (25.60) | 299 (74.40) | ||
| 17.638 | |||||
| N0 | 227 | 100 (44.10) | 127 (55.90) | ||
| N1 | 373 | 102 (27.30) | 271 (72.70) | ||
| 9.728 | |||||
| M0 | 562 | 198 (35.20) | 364 (64.80) | ||
| M1 | 38 | 4 (10.50) | 34 (89.50) | ||
| 7.549 | |||||
| Positive | 475 | 147 (30.9%) | 328 (69.1%) | ||
| Negative | 125 | 55 (44.0%) | 70 (56.0%) | ||
others include: pallipary adenocarcinoma, 5 cases; adeno-squamous carcinoma, 5 cases; squamous cell carcinoma, 3 cases; undifferentiated carcinoma, 2 cases; and neuroendocrine carcinoma, 1 case.
others include everything besides tubular and papillary adenocarcinoma.
p < 0.05.
Univariate and multivariate analysis of prognostic markers for overall survival in gastric cancer
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95%CI | HR | 95%CI | |||
| High vs Low or no | 2.474 | 1.765–3.468 | 1.819 | 1.213–2.728 | ||
| ≤ 60 vs ≥ 60 | 0.733 | 0.057 | 0.532–1.009 | – | – | – |
| Male vs Female | 1.083 | 0.658 | 0.761–1.541 | – | – | – |
| Tubular vs Mixed (tubular and mucinous) vs Mucinous vs signet ring cells vs others | 0.924 | 0.388 | 0.773–1.105 | – | – | – |
| Well vs Moderate vs Poor | 1.168 | 0.115 | 0.963–1.416 | – | – | – |
| 0 vs Ia + Ib vs IIa + IIb vs IIIa + IIIb vs IIIc + IV | 2.245 | 1.870–2.696 | 2.265 | 1.512–3.393 | ||
| Tis vs T1 vs T2 vs T3 vs T4 | 2.320 | 1.758–3.062 | – | – | – | |
| N0 vs N1 vs N2 vs N3 | 3.657 | 2.611–5.123 | – | – | – | |
| M0 vs M1 | 6.614 | 2.317–18.878 | – | – | – | |
| Positive vs Negative | 2.696 | 1.795–4.008 | 2.512 | 1.575–4.006 | ||
others include: pallipary adenocarcinoma, 5 cases; adeno-squamous carcinoma, 5 cases; squamous cell carcinoma, 3 cases; undifferentiated carcinoma, 2 cases; and neuroendocrine carcinoma, 1 case.
p < 0.05.
Figure 3Survival curves for gastric cancer using the Kaplan-Meier method and the log-rank test
(A); a Overall survival curves for patients with low or no Trop2 expression (blue line, 1) and patients with high Trop2 expression of (green line, 2); b disease-free survival curves for patients with low or no Trop2 expression (blue line, 1) and high Trop2 expression (green line, 2). (B) Overall survival curves by TNM stage; TNM 0 (blue line, 1), TNM Ia and Ib (green line, 2), TNM IIa and IIb (grey line, 3), TNM IIIa and IIIb (purple line, 4), TNM IIIc and IV (yellow line, 5). (C) overall survival curves for H. pylori negative (blue line, 1) and positive (green line, 2) patients.